AI-Assisted Precise and Rapid Diagnosis of “Heart Conditions”

Release time:

2025-03-01

In recent years, Chinese enterprises have actively invested in research on the application of AI-powered medical imaging software in the field of cardiovascular diseases, resulting in the approval and launch of several products, primarily focused on niche applications such as coronary CT angiography and electrocardiogram–based auxiliary analysis.

AI-Assisted Precise and Rapid Diagnosis of “Heart Conditions”

AI-powered medical imaging software applied to CCTA can enhance image quality and enable automated measurements. Traditional approaches, such as increasing radiation dose or employing iterative reconstruction algorithms, can reduce noise to some extent; however, when AI is used for CCTA image reconstruction, deep-learning models can effectively suppress noise and improve image quality, thereby mitigating the potential risks associated with high radiation exposure. Prior to performing a CCTA examination, a non-contrast CT scan is typically conducted to obtain the coronary artery calcium score (CACS). AI models can directly perform automated CACS calculation from CCTA data, streamlining the CCTA workflow and reducing radiation exposure. Moreover, when detecting and assessing calcified plaques in CCTA, AI assistance can significantly shorten the examination time. In terms of quantifying coronary stenosis, clinical assessment primarily relies on visual diameter measurement: the degree of stenosis is determined by the percentage reduction in the diameter at the lesion site compared with the normal diameters proximal and distal to the lesion, and the severity is graded according to the Coronary Artery Disease Reporting and Data System (CAD-RADS) classification. Notably, fractional flow reserve (FFR), an index for evaluating coronary blood flow, traditionally requires invasive angiography; in contrast, AI technology can use AI algorithms to perform three-dimensional reconstruction and, combined with fluid-dynamic simulations, derive the corresponding FFR value.

Related News

Overview of Bioanalytical Methods for Cell Therapy Products

Cell and gene therapy (CGT) can be broadly classified, based on product format, into ex vivo gene therapy and in vivo gene therapy.

2026-04-03

Bioanalytical Strategies for CGT Products: Selected Developments and Validation of qPCR/ddPCR Methodologies

With the rapid development of cell and gene therapy (CGT), dozens of CGT products have now been approved for market launch worldwide.

2026-04-03

Pharmaceutical and Biotechnology Industry Watch: Innovative Drugs and Medical Devices Fuel Structured Market Performance; AI in Healthcare Opens New Growth Opportunities

During the third week of February 2025, the pharmaceutical and biotechnology sector continued to exhibit structural divergence. Over the week, the pharmaceutical and biotechnology index rose by 1.88%, outperforming both the CSI 300 Index and the Shanghai Composite Index, ranking ninth in terms of sector performance.

2025-03-01

Pharmaceutical and Biotechnology Industry Watch: AI-Driven Healthcare Applications Accelerate Deployment; Breakthroughs in Payment-Policy for Innovative Drugs

Recently, the pharmaceutical and biotechnology sector has exhibited a pronounced structural market trend, driven by the deep integration of AI technologies with healthcare applications, which is spurring industry upgrades. At the same time, policy support for innovative drugs continues to strengthen, creating multiple favorable factors for the sector.

2025-03-01

With the concerted support of 17 departments, the latest policies for the biopharmaceutical industry in the Jiangsu Pilot Free Trade Zone have been unveiled!

Recently, the “Policy Measures for Coordinated Support from Relevant Provincial Departments for the Open and Innovative Development of the Biopharmaceutical Industry in the China (Jiangsu) Pilot Free Trade Zone” (hereinafter referred to as the “Policy Measures”) were officially released!

2025-03-01

Medical Device Industry Development Report: Significant Market Potential in Countries Along the Belt and Road

Recently, the “Medical Device Blue Book: Report on the Development of China’s Medical Device Industry (2018),” jointly released in Beijing by the China Association for Pharmaceutical Regulatory Research and the Social Sciences Academic Press, stated that since the Belt and Road Initiative was proposed in 2013, demand for Chinese medical device products has increased among countries along the Belt and Road.

2025-03-01

Share